| None |
Opioid |
View
|
| None |
Opioid Addiction |
View
|
| None |
Opioid Dependance |
View
|
| None |
Opioid Withdrawal Symptoms |
View
|
| None |
Opioid Withdrawal Syndrome |
View
|
| None |
Morphine Addiction |
View
|
| None |
delta-opioid receptors |
View
|
| None |
Inhibition of nociceptive afferent neurons (PNS System) |
View
|
| None |
Reduction of nociceptive transmission |
View
|
| None |
Activation of descending inhibitory pathways (CNS System) |
View
|
| None |
Analgesic Opioids |
View
|
| None |
Drug craving |
View
|
| None |
μ-δ-opioid (Mu-Delta) receptor |
View
|
| None |
μ-binding (Mu receptors) |
View
|
| None |
afferents within laminae I and II |
View
|
| None |
κ-opioid receptor (KOR) |
View
|
| None |
δ-opioid receptor (DOR) agonist |
View
|
| None |
(+)-pentazocine |
View
|
| None |
σ receptor antagonists |
View
|
| None |
Downstream involvement of the σ receptor |
View
|
| None |
Increase phosphorylation in p38 MAPK |
View
|
| None |
IL-10 |
View
|
| None |
Activation of IL-12 |
View
|
| None |
IL-12 increase in T-cell immune response |
View
|
| None |
pentacyclic 3°amine (alkaloid) |
View
|
| None |
stereogenic centers |
View
|
| None |
tetrahydroisoquinoline reticuline |
View
|
| None |
CPY2D6 |
View
|
| None |
benzylisoquinoline alkaloid |
View
|
| None |
p38 MAPK-dependent pathway |
View
|
| None |
kappa-opioid receptors |
View
|
| None |
Short Opiate Withdrawal Scale (SOWS)-Gossop |
View
|
| None |
Clinical Opiate Withdrawal Scale (COWS) |
View
|
| None |
Agitation and Calmness Evaluation Scale (ACES) |
View
|
| None |
Discontinuation of Morphine Maintenance |
View
|